The presence of estrogen receptors in breast cancers is now accepted as a predictor of extended disease-free survival, but the relative value of progesterone receptors for this purpose has not been established. We have examined both receptors along with other risk factors in 189 patients receiving adjuvant therapy for Stage II breast cancer. The presence of either estrogen receptors or progesterone receptors was positively correlated with disease-free survival when analyzed separately, whether or not the adjuvant regimen included an endocrine component. However, when estrogen receptors and progesterone receptors were analyzed together in multivariate models, the presence of progesterone receptors was more significant than that of estrogen receptors for predicting time to recurrence, regardless of what other variables were included in the model. These data suggest that determination of the progesterone-receptor concentration is of equal or greater value than determination of the estrogen-receptor concentration for predicting the disease-free survival of patients with breast cancer. Future trials should include measurement of progesterone receptors.
This article has been cited by other articles:
McGowan, E. M., Russell, A. J., Boonyaratanakornkit, V., Saunders, D. N., Lehrbach, G. M., Sergio, C. M., Musgrove, E. A., Edwards, D. P., Sutherland, R. L.
(2007). Progestins Reinitiate Cell Cycle Progression in Antiestrogen-Arrested Breast Cancer Cells through the B-Isoform of Progesterone Receptor. Cancer Res.
67: 8942-8951
[Abstract][Full Text]
Gizard, F., Robillard, R., Barbier, O., Quatannens, B., Faucompre, A., Revillion, F., Peyrat, J.-P., Staels, B., Hum, D. W.
(2005). TReP-132 Controls Cell Proliferation by Regulating the Expression of the Cyclin-Dependent Kinase Inhibitors p21WAF1/Cip1 and p27Kip1. Mol. Cell. Biol.
25: 4335-4348
[Abstract][Full Text]
Gold, B., Kalush, F., Bergeron, J., Scott, K., Mitra, N., Wilson, K., Ellis, N., Huang, H., Chen, M., Lippert, R., Halldorsson, B. V., Woodworth, B., White, T., Clark, A. G., Parl, F. F., Broder, S., Dean, M., Offit, K.
(2004). Estrogen Receptor Genotypes and Haplotypes Associated with Breast Cancer Risk. Cancer Res.
64: 8891-8900
[Abstract][Full Text]
Schwarz, C., Lubbert, H., Rahn, W., Schonfeld, N., Serke, M., Loddenkemper, R.
(2004). Medical thoracoscopy: hormone receptor content in pleural metastases due to breast cancer. Eur Respir J
24: 728-730
[Abstract][Full Text]
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., Quebe-Fehling, E., Borgs, M.
(2001). Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1- and/or ErbB-2-Positive, Estrogen Receptor-Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial. JCO
19: 3808-3816
[Abstract][Full Text]
Roth, K. A., Brenner, J. W., Selznick, L. A., Gokden, M., Lorenz, R. G.
(1997). Enzyme-based Antigen Localization and Quantitation in Cell and Tissue Samples (Midwestern Assay). J. Histochem. Cytochem.
45: 1629-1642
[Abstract][Full Text]
Groshong, S. D., Owen, G. I., Grimison, B., Schauer, I. E., Todd, M. C., Langan, T. A., Sclafani, R. A., Lange, C. A., Horwitz, K. B.
(1997). Biphasic Regulation of Breast Cancer Cell Growth by Progesterone: Role of the Cyclin-Dependent Kinase Inhibitors, p21 and p27Kip1. Mol. Endocrinol.
11: 1593-1607
[Abstract][Full Text]
Slamon, D., Clark, G.
(1988). Amplification of c-erbB-2 and aggressive human breast tumors?. Science
240: 1795-1798
Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A, McGuire, W.
(1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science
235: 177-182
[Abstract]
Previous
